WO2011128434A3 - Treatment of endocrine resistant breast cancer - Google Patents

Treatment of endocrine resistant breast cancer Download PDF

Info

Publication number
WO2011128434A3
WO2011128434A3 PCT/EP2011/056003 EP2011056003W WO2011128434A3 WO 2011128434 A3 WO2011128434 A3 WO 2011128434A3 EP 2011056003 W EP2011056003 W EP 2011056003W WO 2011128434 A3 WO2011128434 A3 WO 2011128434A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
breast cancer
resistant breast
endocrine resistant
endocrine
Prior art date
Application number
PCT/EP2011/056003
Other languages
French (fr)
Other versions
WO2011128434A2 (en
Inventor
Mitch Dowsett
Zara Ghazoui
Lesley-Ann Martin
Christoph Mundhenke
Marion Weigel
Original Assignee
Novartis Ag
Institute Of Cancer Research: Royal Cancer Hospital
Universitätsklinikum Schleswig-Holstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Institute Of Cancer Research: Royal Cancer Hospital, Universitätsklinikum Schleswig-Holstein filed Critical Novartis Ag
Priority to JP2013504289A priority Critical patent/JP2013525296A/en
Priority to EP11716500A priority patent/EP2558098A2/en
Publication of WO2011128434A2 publication Critical patent/WO2011128434A2/en
Publication of WO2011128434A3 publication Critical patent/WO2011128434A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to pyrimidylaminobenzamides of formula (I) and other suitable PDGF-R inhibitors, alone or in combination with at least one aromatase inhibitor for the treatment of endocrine resistant breast cancer and to a method of treating warm-blooded animals including humans suffering from endocrine resistant breast cancer by administering to a said animal in need of such treatment an effective dose of a pyrimidylaminobenzamide of formula I alone or in combination with an aromatase inhibitor.
PCT/EP2011/056003 2010-04-16 2011-04-15 Treatment of endocrine resistant breast cancer WO2011128434A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2013504289A JP2013525296A (en) 2010-04-16 2011-04-15 Treatment of endocrine therapy-resistant breast cancer
EP11716500A EP2558098A2 (en) 2010-04-16 2011-04-15 Treatment of endocrine resistant breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160113 2010-04-16
EP10160113.6 2010-04-16

Publications (2)

Publication Number Publication Date
WO2011128434A2 WO2011128434A2 (en) 2011-10-20
WO2011128434A3 true WO2011128434A3 (en) 2011-12-22

Family

ID=42136083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/056003 WO2011128434A2 (en) 2010-04-16 2011-04-15 Treatment of endocrine resistant breast cancer

Country Status (3)

Country Link
EP (1) EP2558098A2 (en)
JP (1) JP2013525296A (en)
WO (1) WO2011128434A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2007115289A2 (en) * 2006-04-05 2007-10-11 Novartis Ag Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
JP2710053B2 (en) 1988-07-05 1998-02-10 スズキ株式会社 Car body structure
GT200600316A (en) 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
GT200600315A (en) 2005-07-20 2007-03-19 CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005281A1 (en) * 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2007115289A2 (en) * 2006-04-05 2007-10-11 Novartis Ag Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AHLGREN M THIRLWELL R O'REGAN C MORMONT L LEVESQUE R GASPO M WOLOJ A BELLO B MARTELL B LEYLAND-JONES P ET AL: "Sunitinib plus exemestane for the first-line treatment of hormone receptor-positive metastatic breast cancer: Results of an open-label study", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY.ASCO, THE SOCIETY, US, 1 January 2009 (2009-01-01), XP009138666, ISSN: 1081-0641, [retrieved on 20100913] *
B. ARUN, J. L. MURRAY, R. WALTERS, A. BREWSTER, E. RIVERA, V. VALERO, R. BAST, R. L. THERIAULT, M. GREEN, M. GREEN,: "The combination of letrozole and imatinib mesylate for metastatic breast cancer", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY.ASCO, THE SOCIETY, US, 1 January 2009 (2009-01-01), pages 214, XP009138741 *
BRAMA MARINA ET AL: "Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment", ENDOCRINE-RELATED CANCER, vol. 14, no. 1, March 2007 (2007-03-01), pages 61 - 72, XP002600758, ISSN: 1351-0088 *
BRUEGGEMEIER R W ET AL: "AROMATASE INHIBITORS IN THE TREATMENT OF BREAST CANCER", ENDOCRINE REVIEWS, BALTIMORE, MD, US, vol. 26, no. 3, 1 January 2005 (2005-01-01), pages 331 - 345, XP009059540 *
CHOW ET AL: "Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 262, no. 2, 14 January 2008 (2008-01-14), pages 232 - 238, XP022552580, ISSN: 0304-3835 *
CHU DAVID ET AL: "Novel therapies in breast cancer: what is new from ASCO 2008", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 1, no. 1, 1 October 2008 (2008-10-01), pages 16, XP021045985, ISSN: 1756-8722, DOI: 10.1186/1756-8722-1-16 *
COXON ANGELA ET AL: "Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 JAN 2009 LNKD- PUBMED:19118038, vol. 15, no. 1, 1 January 2009 (2009-01-01), pages 110 - 118, XP002600759, ISSN: 1078-0432 *
See also references of EP2558098A2 *
WEIGEL M T ET AL: "Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling", CANCER LETTERS, NEW YORK, NY, US LNKD- DOI:10.1016/J.CANLET.2008.07.040, vol. 273, no. 1, 8 January 2009 (2009-01-08), pages 70 - 79, XP025685877, ISSN: 0304-3835, [retrieved on 20080921] *

Also Published As

Publication number Publication date
JP2013525296A (en) 2013-06-20
EP2558098A2 (en) 2013-02-20
WO2011128434A2 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
EA201890768A2 (en) TREATMENT OF MALIGNANT TUMOR INHIBITORS TOR-KINASE
EP3520793A3 (en) Substances and compostions for use in methods of inhibiting muscle atrophy
BR112013002012A2 (en) Methods and Compositions for Liver Cancer Therapy
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
WO2012142498A3 (en) Mif inhibitors and their uses
EA201490369A1 (en) METHODS OF CANCER TREATMENT USING ANTAGONISTS CONNECTING THE AXIS PD-1 AND MEK INHIBITORS
IN2012DN03883A (en)
MY163031A (en) Method of treating obesity using antioxidant inflammation modulators
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
MX344590B (en) Pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof.
MX2012010212A (en) Thioxanthone-based autophagy inhibitor therapies to treat cancer.
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
TN2014000086A1 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
MX2017011018A (en) Inhibition of olig2 activity.
MX2013010524A (en) Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer.
EP2536432A4 (en) Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
TN2009000486A1 (en) Raf inhibitors for the treatment of thyroid cancer
WO2011128434A3 (en) Treatment of endocrine resistant breast cancer
WO2012024670A3 (en) Composition and methods for treating glioblastoma
GB201004761D0 (en) Method
EP2550532A4 (en) Method of supressing cancer, increasing weight loss and/or increasing insulin sensitivity
MX356278B (en) Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor.
WO2009138780A3 (en) Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11716500

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011716500

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013504289

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE